ARVN on Nasdaq
Arvinas (United States)
Company in New Haven, United States.1
Price unavailable
Last updated Oct 16, 2026.
Overview
Jan 1, 2013Founded1
Compare with LIGAND PHARMACEUTICALS INC, Vireo Growth Inc. or Schrödinger, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-45.1%Operating margin4
-30.8%Net margin4
-0.3%Revenue growth, 20254
-18.6%Return on equity4
0.00×Debt to equity4
-$275.7MFree cash flow4
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development100¢$285.2M
- Income tax0¢$300.0K
Out of $262.6M in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | $262.6M | $263.4M | $78.5M |
| Research and development | $285.2M | $348.2M | $379.7M |
| General and administrative | $95.9M | $165.4M | $100.3M |
| Total operating expenses | $381.1M | $513.6M | $480.0M |
| Loss from operations | -$118.5M | -$250.2M | -$401.5M |
| Other expense, net | -$400.0K | -$2.9M | -$1.2M |
| Interest income, net | $38.4M | $54.8M | $38.8M |
| Total other income | $38.0M | $51.9M | $37.6M |
| Net loss before income taxes and loss from equity method investment | -$80.5M | -$198.3M | -$363.9M |
| Income tax expense | -$300.0K | -$600.0K | -$900.0K |
| Loss from equity method investment | $0 | $0 | -$2.5M |
| Net loss | -$80.8M | -$198.9M | -$367.3M |
| Net loss per common share - basic (in dollars per share) | -$1.14 | -$2.77 | -$6.62 |
| Net loss per common share - diluted (in dollars per share) | -$1.14 | -$2.77 | -$6.62 |
| Weighted-average common shares outstanding - basic (in shares) | 70.9M shares | 71.9M shares | 55.5M shares |
| Weighted-average common shares outstanding - diluted (in shares) | 70.9M shares | 71.9M shares | 55.5M shares |
| Unrealized gain on available-for-sale securities | $200.0K | $4.1M | $16.1M |
| Comprehensive loss | -$80.6M | -$194.8M | -$351.2M |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $142.9M | $100.5M | $311.7M |
| Marketable securities | $542.5M | $938.9M | |
| Accounts receivable | $1.0M | $5.7M | $0 |
| Other receivables | $5.4M | $8.0M | |
| Prepaid expenses and other current assets | $8.9M | $14.2M | |
| Total current assets | $700.7M | $1.1B | |
| Property, equipment and leasehold improvements, net | $5.2M | $7.0M | |
| Operating lease right of use assets | $8.2M | $9.0M | |
| Collaboration contract asset and other assets | $3.8M | $8.1M | |
| Total assets | $717.9M | $1.1B | |
| Accounts payable and accrued liabilities | $69.5M | $71.8M | |
| Deferred revenue | $71.3M | $156.2M | |
| Current portion of operating lease liability | $1.7M | $1.8M | |
| Total current liabilities | $142.5M | $229.8M | |
| Deferred revenue | $134.3M | $292.0M | |
| Long term debt | $400.0K | $600.0K | |
| Operating lease liability | $6.8M | $7.3M | |
| Total liabilities | $284.0M | $529.7M | |
| Preferred stock, $0.001 par value, zero shares issued and outstanding as of December 31, 2025 and 2024, respectively | $0 | $0 | |
| Common stock, $0.001 par value, 73.5 shares issued and 63.5 shares outstanding as of December 31, 2025, and 68.8 shares issued and outstanding as of December 31, 2024 | $100.0K | $100.0K | |
| Accumulated deficit | -$1.6B | -$1.5B | |
| Additional paid-in capital | $2.1B | $2.1B | |
| Accumulated other comprehensive income | $1.2M | $1.0M | |
| Treasury Stock, at cost (10.0 and zero shares at December 31, 2025 and December 31, 2024, respectively) | -$91.9M | $0 | |
| Total stockholders' equity | $433.9M | $561.7M | $660.0M |
| Total liabilities and stockholders' equity | $717.9M | $1.1B | |
| Preferred stock par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares issued (in shares) | 73.5M shares | 68.8M shares | |
| Common stock, shares outstanding (in shares) | 63.5M shares | 68.8M shares | |
| Treasury stock, shares (in shares) | 10.0M shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$80.8M | -$198.9M | -$367.3M |
| Depreciation and amortization | $3.0M | $4.6M | $4.8M |
| Net accretion of bond discounts/premiums | -$12.8M | -$21.8M | -$16.6M |
| Loss on sale of marketable securities | $0 | $0 | $900.0K |
| Amortization of right-of-use assets | $2.2M | $2.0M | $1.9M |
| Amortization of collaboration contract asset | $4.3M | $4.6M | $1.3M |
| Net loss on disposal of property, equipment and leasehold improvements | $0 | $2.6M | $0 |
| Stock-based compensation | $44.0M | $88.2M | $71.6M |
| Accounts receivable | $4.7M | -$5.7M | $1.0M |
| Other receivables | $2.6M | -$800.0K | -$200.0K |
| Prepaid expenses and other assets | $5.3M | -$7.0M | $14.1M |
| Collaboration contract asset | $0 | -$3.0M | $0 |
| Accounts payable and accrued liabilities | -$1.7M | -$21.2M | $17.3M |
| Operating lease liabilities | -$2.0M | -$1.9M | -$2.0M |
| Deferred revenue | -$242.6M | -$101.0M | -$74.6M |
| Net cash used in operating activities | -$273.8M | -$259.3M | -$347.8M |
| Purchase of marketable securities | -$354.2M | -$652.1M | -$956.3M |
| Maturities of marketable securities | $731.1M | $644.0M | $1.1B |
| Sale of marketable securities | $32.6M | $44.5M | $58.8M |
| Purchase of property, equipment and leasehold improvements | -$1.9M | -$1.8M | -$2.9M |
| Proceeds from disposal of property, equipment and leasehold improvements | $0 | $100.0K | $0 |
| Net cash provided by investing activities | $407.6M | $34.7M | $203.5M |
| Repayments of long-term debt | -$200.0K | -$400.0K | $0 |
| Proceeds from issuance of common stock and pre-funded warrants | $0 | $0 | $387.2M |
| Payment of common stock offering costs | $0 | $0 | -$17.0M |
| Repurchase of common shares, net | -$91.9M | $0 | $0 |
| Proceeds from exercise of stock options and issuance of ESPP shares | $700.0K | $8.3M | $4.5M |
| Net cash (used in) provided by financing activities | -$91.4M | $7.9M | $374.7M |
| Net increase (decrease) in cash, cash equivalents and restricted cash | $42.4M | -$216.7M | $230.4M |
| Purchases of property, equipment and leasehold improvements unpaid at period end | $300.0K | $900.0K | $0 |
Former names
Timeline
- Jan 1, 2013Founded Founded1
Recent filings
- Sep 28, 2026S-8
- Sep 22, 2026144
- Sep 9, 2026144
- Sep 4, 2026144
- Aug 31, 2026S-8
- Aug 14, 2026SCHEDULE 13G/A
- Aug 4, 20268-K
- Aug 4, 202610-Q
- Aug 4, 2026144
- Jul 9, 2026144
- Jun 26, 20264
- Jun 26, 20264
- Jun 26, 20264
- Jun 26, 20264
- Jun 26, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitearvinas.com1
- WikidataQ61934485
- SEC EDGARCIK 1655759
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12